µÏÍþ¹ú¼Ê

µÏÍþÖÆµÏÍþ¹ú¼Ê µÏÍþÖÆµÏÍþ¹ú¼Ê

¼ò ¤™
  • ¼ò
  • ·±
  • EN
¤œ
Ïà¹ØÁ´½Ó
  • ½­ËÕºÀÉ­µÏÍþ¹ú¼ÊÒµ¼¯ÍÅÓÐÏÞ¹«Ë¾¥Y
ÐÂÎÅ·¢²¼
Press Release
Ê×Ò³  >  ÐÂÎÅÖÐÐÄ  >  ÐÂÎÅ·¢²¼
µÏÍþÖÆµÏÍþ¹ú¼Ê´´ÐµÏÍþ¹ú¼ÊæÚÀ´ÃÀ?Ê׸öÖÎÁÆÌÇÄò²¡Éö²¡µÄÁÙ´²Ö¤¾Ý·¢±í
·¢²¼ÈÕÆÚ£º2024/07/22
×ÖºÅ

½üÈÕ£¬µÏÍþÖÆµÏÍþ¹ú¼ÊÔ­Ñд´ÐµÏÍþ¹ú¼ÊæÚÀ´ÃÀ?£¨¾ÛÒÒ¶þ´¼ÂåÈûÄÇëÄ×¢ÉäÒº£©ÖÎÁÆÌÇÄò²¡Éö²¡£¨DKD£©»¼ÕßµÄËæ»úÁÙ´²Ñо¿½á¹ûÔÚFrontiers in Endocrinology£¨¡¶ÄÚ·ÖÃÚÑ§Ç°ÑØ¡·£©ÔÓÖ¾·¢±í¡£Êý¾Ý±íÃ÷£¬æÚÀ´ÃÀ?ÁÆÐ§Óë´ï¸ñÁо»Ï൱ÇÒ¸ÄÉÆÖ¬ÖÊˮƽ¸ü¾ßÓÅÊÆ¡£



ÕâÏîµ¥ÖÐÐÄ¡¢Ëæ»ú¡¢¿ª·Å±êÇ©ÁÙ´²ÊÔÑ飬¹²ÕÐļ106ÀýÇáÖжÈDKDºÍѪÌÇ¿ØÖÆÇ·¼ÑµÄ»¼Õߣ¬Ëæ»ú½ÓÊܾÛÒÒ¶þ´¼ÂåÈûÄÇëĺʹï¸ñÁо»ÖÎÁÆ£¬Ö¼ÔڱȽÏÁ½ÖÖµÏÍþ¹ú¼ÊÎïÔÚ´ËÀ໼ÕßÖеÄÁÆÐ§ºÍ°²È«ÐÔ¡£Ö÷ÒªÖÕµãÊÇ24ÖÜʱÄò°×µ°°×/¼¡ôû±ÈÖµ£¨UACR£©×Ô»ùÏߵı仯(1)¡£

ÁÙ´²Ñо¿½á¹ûÏÔʾ£¬ÖÎÁÆ24Öܺ󣬾ÛÒÒ¶þ´¼ÂåÈûÄÇëÄ×éºÍ´ï¸ñÁо»×éµÄUACR×Ô»ùÏß·Ö±ðÆ½¾ùϽµ29.3%ºÍ31.8%£¬ÎÞͳ¼ÆÑ§ÏÔÖø²îÒ죨p = 0.336£©£¬Òâζ×ÅÁ½ÕßÔÚ¸ÄÉÆÄòµ°°×·½ÃæµÄÁÆÐ§Ï൱¡£´ËÍ⣬Á½×éÔÚ½µµÍѪÌǺͼõÖØ·½ÃæµÄÁÆÐ§Ò²Ï൱£¬µ«¾ÛÒÒ¶þ´¼ÂåÈûÄÇëÄ×éÔÚ½µµÍ¿Õ¸¹ÑªÌÇ£¨FPG£©Ë®Æ½ÉÏÏÔʾ³öÂÔÓŵÄÇ÷ÊÆ¡£ÖµµÃ×¢ÒâµÄÊÇ£¬¾ÛÒÒ¶þ´¼ÂåÈûÄÇëÄ×éµÄ¸ÊÓÍÈýõ¥£¨TG£©Ë®Æ½Ï½µ¸üΪÏÔÖø£¨-0.56 vs -0.33 mmol/L£¬p = 0.023£©¡£ÔÚÆäËüѪָ֬±êÒÔ¼°ÑªÑ¹Ö¸±êÉÏÁ½×é¾ù½Ó½ü¡£°²È«ÐÔ·½ÃæÒ²ÓëÏÈǰµÄÑо¿½á¹ûÒ»Ö£¬¾ÛÒÒ¶þ´¼ÂåÈûÄÇëÄ×ÜÌåÄÍÊÜÐÔÁ¼ºÃ£¬Î´·¢ÏÖÐµİ²È«ÐÔʼþ(1)¡£

DKDÊÇÌÇÄò²¡µÄÒ»ÖÖ΢Ѫ¹Ü²¢·¢Ö¢£¬´óÔ¼10%-40%µÄÌÇÄò²¡»¼Õ߻ᷢÉúDKD£¬ÁÙ´²±íÏÖΪ³ÖÐøµÄµ°°×ÄòºÍ/»òÉöСÇòÂ˹ýÂÊ£¨GFR£©Öð½¥Ï½µ£¬×îÖտɵ¼ÖÂÖÕÄ©ÆÚÉöÔ༲²¡£¨ESRD£©¡£´ËÍ⣬DKD»¹»áÏÔÖøÌá¸ß2ÐÍÌÇÄò²¡»¼ÕßµÄÐÄѪ¹ÜʼþºÍÈ«ÒòËÀÍö·çÏÕ(2)¡£

SGLT2ÒÖÖÆ¼Á£¬Èç´ï¸ñÁо»µÈ£¬¾ßÓнµÌÇÒÔÍâµÄÉöÔà±£»¤×÷Óã¬ÒÑ»ñµÃ¹úÄÚÖ¸ÄÏÍÆ¼öÈϿɣ¬×÷ΪÖÎÁÆDKDµÄÒ»Ïß½µÌÇÓõÏÍþ¹ú¼Ê(2)¡£GLP-1ÊÜÌ弤¶¯¼ÁÒ²ÓÐÖú¸ÄÉÆDKDÉöÔà½á¾Ö(2)£¬È»¶ø£¬¾ÛÒÒ¶þ´¼ÂåÈûÄÇëÄÔÚDKD»¼ÕßÖеÄÓÐЧÐԺͰ²È«ÐÔÉÐδ¼ûÖµÀ¡£

±¾´Î·¢±íµÄÑо¿Êý¾ÝΪ¾ÛÒÒ¶þ´¼ÂåÈûÄÇëÄÔÚDKD»¼ÕßÖеÄʹÓÃÌṩÁËÖØÒªÑ­Ö¤ÒÀ¾Ý£¬½«ÎªÇáÖжÈDKD»¼ÕßÌṩеÄÖÎÁÆÓÅÑ¡¡£

²Î¿¼ÎÄÏ×£º

[1] Cao Y, Cao S, Zhao J, Zhao J, Zhao Y and Liu Y (2024) Efficacy and safety of polyethylene glycol loxenatide in treating mild-to-moderate diabetic kidney disease in type 2 diabetes patients: a randomized, open-label, clinical trial. Front Endocrinol. 15:1387993.
[2] ÖлªÒ½Ñ§»áÌÇÄò²¡Ñ§·Ö»á΢Ѫ¹Ü²¢·¢Ö¢Ñ§×é. ÖйúÌÇÄò²¡ÉöÔ༲²¡·ÀÖÎÁÙ´²Ö¸ÄÏ [J] . ÖлªÌÇÄò²¡ÔÓÖ¾, 2019, 11(1) : 15-28.


¹ØÓÚµÏÍþ

µÏÍþÖÆµÏÍþ¹ú¼ÊÊÇÖйúÁìÏȵĴ´ÐÂÇý¶¯ÐÍÖÆµÏÍþ¹ú¼ÊÆóÒµ£¬ÏÂÊôºÀÉ­µÏÍþ¹ú¼ÊÒµ¡¢³£Öݺã°îµÏÍþ¹ú¼ÊÒµ¡¢µÏÍþÉúÎïÒ½µÏÍþ¹ú¼ÊµÈ×Ó¹«Ë¾£¬ÖØµã¹Ø×¢¿¹Ö×Áö¡¢¿¹¸ÐȾ¡¢ÖÐÊàÉñ¾­ÏµÍ³¡¢´úл¼°×ÔÉíÃâÒßµÈÖØ´ó¼²²¡ÖÎÁÆÁìÓò£¬ÖÂÁ¦ÓÚͨ¹ý³ÖÐø´´ÐÂÌá¸ßÈËÀàÉúÃüÖÊÁ¿¡£½ØÖÁĿǰ£¬¹«Ë¾ÒÑÉÏÊÐ7¿î´´ÐµÏÍþ¹ú¼Ê£¬´´Ð²úÆ·ÓªÊÕÕ¼±È´ï67.9%¡£¹«Ë¾Á¬Ðø¶àÄêλ¾ÓÈ«ÇòÖÆµÏÍþ¹ú¼ÊÆóÒµ°ÙÇ¿¡¢ÖйúÒ½µÏÍþ¹ú¼ÊÑз¢²úÆ·Ïß×î¼Ñ¹¤ÒµÆóҵǰ3Ç¿£¬Êǹú¼ÒÖØµã¸ßм¼ÊõÆóÒµ¡¢¹ú¼Ò¼¼Êõ´´ÐÂʾ·¶ÆóÒµ¡£¹«Ë¾ÓÚ2019Äê6ÔÂÔÚÏã¸ÛÁª½»Ëù¹ÒÅÆÉÏÊУ¨¹ÉƱ´úÂ룺03692.HK£©¡£¸ü¶àÐÅÏ¢Çë·ÃÎÊ£º/¡£



ǰհÐÔ˵Ã÷

±¾ÎÄÖ¼ÔÚÌṩÓйء°µÏÍþÖÆµÏÍþ¹ú¼Ê¼¯ÍÅÓÐÏÞ¹«Ë¾¡±»òÆä×Ó¹«Ë¾µÈ¹ØÁª·½£¨Í³³Æ¡°¹«Ë¾¡±£©µÄÏà¹ØÐÅÏ¢£¬²»¹¹³É¹«Ë¾ÐÅÏ¢Åû¶»òͶ×ÊÍÆ¼ö¡£

±¾ÎÄËù·¢²¼µÄÐÅÏ¢ÖпÉÄÜ»á°üº¬Ä³Ð©Ç°Õ°ÐÔ±íÊö£¬ÀýÈçÉæ¼°ÒµÎñºÍ²úƷǰ¾°£¬»ò¹«Ë¾¼Æ»®¡¢ÈÏÖª¡¢Ô¤ÆÚ¼°²ßÂÔ¡£ÕâЩ±íÊöÊǽ¨Á¢ÔÚÍÆ²âÐÔ¼ÙÉèµÄÊý¾Ý»ù´¡ÉϵÄÔ¤²â£¬²¢·ÇÊǶÔδÀ´·¢Õ¹µÄ±£Ö¤£¬ÒòÆäÐÔÖÊʹȻ¾ùÊÜÏà¹Ø·çÏպͲ»È·¶¨ÒòËØÓ°Ï죬ÆäÖв¿·Ö»¹²»Êܹ«Ë¾¿ØÖÆÇÒÄÑÒÔÔ¤ÁÏ£¬Í¶×ÊÕß½øÐÐͶ×ʾö²ßʱӦ½÷É÷ʹÓá£ÔÚʹÓá°ÖÂÁ¦ÓÚ¡±¡°Ô¤ÆÚ¡±¡°ÏàÐÅ¡±¡°Ô¤²â¡±¡°ÆÚÍû¡±¼°ÆäËûÀàËÆ´ÊÓï½øÐбíÊöʱ£¬·²Ó빫˾ÓйصÄÐÅÏ¢±íÊö£¬¾ùÊôÓÚǰհÐÔ±íÊö¡£¹«Ë¾²¢ÎÞÒåÎñ¸üлòÐÞ¸ÄÕâЩǰհÐÔ±íÊö£¬¹«Ë¾¡¢¹«Ë¾¶­Ê¡¢¹ÍÔ±¡¢´úÀí¸Å²»³Ðµ£ÒòÈκÎǰհÐÔ±íÊö²»ÄÜʵÏÖ»ò±ä³É²»ÕýÈ·¶øÒýÖµÄÈκÎÔðÈΡ£

±¾ÐÂΟåÖеÄËùÓÐÐÅÏ¢½ö¼°ÓÚÐÂΟ巢²¼Ö®ÈÕ£¬ÎÞÂÛÊÇ·ñ³öÏÖÐÂ×ÊÁÏ¡¢Î´À´Ê¼þ»òÆäËûÇé¿ö£¬³ý·Ç·¨ÂÉÒªÇ󣬹«Ë¾²¢ÎÞÔðÈλòÒåÎñ¸üлòÐ޸ĸõÈÐÅÏ¢¡£Í¶×ÊÕßÒ˲ÎÕÕµÏÍþÖÆµÏÍþ¹ú¼Ê£¨03692.HK£©¹«¸æ¼°²Æ±¨£¬ÒÔ»ñÈ¡½öÓëÉÏÊй«Ë¾ÓйصÄÐÅÏ¢¡£




¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿